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It is well documented that chemical carcinogenesis results in
tumours that are resistant to the cytotoxic and growth
inhibitory effects of various carcinogens [Carr, 1987]. Inter-
estingly, there exists a remarkable parallel between the
biochemical changes with carcinogen resistance and
multidrug-resistance. The most frequently reported alteration
in multidrug resistant cells, namely the overexpression of the
170 kDa membrane glycoprotein, is also found in both
preneoplastic and neoplastic lesions producd by carcinogens
[Thorgeirsson et al., 1987; Fairchild et al., 1987; Burt &
Thorgeirsson, 1988; Burt et al., 1988; Gottesman, 1988; Volm
et al., 1990]. Since human lung carcinoma is predominantly
caused by cigarette smoking [Doll & Peto, 1981] the question
arises whether lung tumours of smokers tend to be
chemoresistant more frequently than tumours occurring in
nonsmokers. To answer this question we determined the
resistance of human non-small cell lung carcinomas and com-
pared these results with the cigarette smoking habits of the
patients.
One hundred and sixty patients with previously untreated
non-small cell lung carcinomas were entered into this inves-
tigation (Table I). The morphological classification of the
carcinomas was based on the WHO recommendations
[World Health Organization, 1981]. All patients were staged
at the time of surgery. Staging (pTNM) was performed ac-
cording to the guidelines of the American Joint Committee
for Cancer Staging and End Results Reporting [Carr &
Mountain, 1977]. Eleven per cent of the smokers smoked
fewer than 10 cigarettes, 19%, 10 to 19, 38%, 20 to 29, 12%,
30 to 39, and 19% more than 40 cigarettes daily.
Most of the patients were treated by surgical procedures
alone, or by combined surgical and radiation therapy. For
this reason we used an in vitro short-term test for determin-
ing the resistance of the tumours to drugs. The short-term
test for predicting resistance to chemotherapy has been des-
cribed previously [Volm et al., 1979; Group of Sensitivity
Testing of Tumours (KSST), 1981]. Its basic feature is
measurement of changes in the incorporation of radioactive
nucleic acid precursors into cell suspensions made from fresh
tumour biopsies after addition of doxorubicin. The suspen-
sions were incubated with different concentrations of doxo-
rubicin for 3 h. Subsequently, the acid-insoluble radioactivity
was measured by scintillation counting. The test threshold
between sensitive and resistant tumours was derived from an
earlier clinical study [Group of Sensitivity Testing of
Tumours (KSST), 1981]. Although we cannot separate
tumour cells and stromal cells within the tumour cell suspen-
sions, in general, resistant tumours are predictable with a
high accuracy in the in vitro short-term test. In a co-operative
study [Group of Sensitivity Testing of Tumours (KSST),
1981; Volm et al., 1983] conducted by nine different hos-
pitals, results of the short-term test were compared with
results of chemotherapy in patients. If the alternative evalua-
tions (progression or remission) are compared with the in
vitro results, 56 of the 57 tumours that were resistant in the
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test were clinically progressive (98%) and 40 of 58 tumours
that tested sensitive showed clinical remission (69%). There
was also good agreement between the in vitro test results and
survival. Similar results were obtained in subsequent studies
[Volm et al., 1985a,b, 1988]. These results have recently been
confirmed by Khoo et al. (1989) and Auner et al. (1989).
As expected, the lung tumours in the present study re-
sponded very differently in the in vitro test system. Forty-one
(25%) out of 160 tumours were classified as sensitive and 119
tumours (75%) as resistant. In Table II the relationship
between test results in vitro (sensitive/resistant) and smoking
(nonsmokers/smokers) of all analysed non-small cell lung
carcinomas are presented. A significant relationship between
smoking and response of the tumours to doxorubicin in vitro
was found (P = 0.002). Carcinomas of smokers tended to be
resistant more frequently (81%) than carcinomas of non-
smokers (53%). Similar results were obtained when the
analysis was restricted only to those patients with epidermoid
lung carcinomas (P = 0.001). Of the tumours of smokers
91%, and of the tumours of non-smokers 50% were resis-
tant. In contrast to these data there exists no relationship
Table I Patient characteristics
Clinical characteristics No. ofpatients
Age
<40
40-49
50-59
60-69
, 70
Sex
male
female
Histology
Epidermoid Ca
Adeno Ca
Large cell Ca
Stage
I
II
III
Smoking habits*
Nonsmokers
Smokers
5
18
75
47
15
142
18
88
49
23
33
17
110
32
127
*One case of large cell carcinoma could not be categorised.
Table II Relationship between resistance and smoking habits of
patients with non-small lung carcinomas
Nonsmokers Smokers
Test results n (%) n (%) P
All tumours sensitive 15 (47) 24 (19) 0 002
resistant 17 (53) 103 (81)
Epidermoid Ca sensitive 7 (50) 7 (9) 0.001 resistant 7 (50) 67 (91)
Adeno Ca sensitive 6 (38) 13 (39)
resistant 10 (62) 20 (61) n.s.
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between resistance and smoking for adenocarciomas of the
lung. This may be expected because adenocarcinomas are
said to be less frequently associated with smoking than are
epidermoid lung carcinomas [Gould & Warren, 1989]. We
further analysed the patients with regard to the number of
cigarettes smoked and to cessation of smoking and could not
find any influence of these factors (data not shown).
Until now, the mechanisms for the resistance of lung
tumours are unknown and may be multifactorial. It can be
speculated that, as a detoxifying transport system, the
P-glycoprotein might be increased with other known detoxi-
fying systems such as glutathione transferase, cytochrome
P-450 isoforms and topoisomerase II. Whereas Lai et al.
(1989) demonstrated only a weak expression of the
multidrug-resistance (MDR) gene in 14 out of 24 human
lung tumours, Radosevich et al. (1989) found P-glycoprotein
expressing cells in 100 out of 131 non-small cell lung car-
cinomas by immunohistochemical techniques. We recently
investigated the intrinsic resistance of a panel of human
epidermoid lung cancer xenografts grown in nude mice [Volm
et al., 1989b] and found a correlation between expression of
P-glycoprotein and degree of resistance. Carmichael et al.
(1988) measured glutathione levels in 30 human lung cancer
lines and found lower levels in cell lines derived from small
cell lung cancer specimens compared to non-small cell lung
cancer. Non-small cell lung cancers were found to have
increased activity of 4 detoxification enzymes (glutathione
transferase, glutathione reductase, y-glutamyl transpeptidase,
superoxide dismutase) compared to small cell lung tumours.
These differences in glutathione levels and detoxification
enzyme levels may also prove to be important causes for
intrinsic drug resistance often seen in patients with non-small
cell lung cancer. Zijlstra et al. (1987) demonstrated that the
resistance in a doxorubicin-resistant human lung carcinoma
cell line was multifactorial with decreased intracellular dox-
orubicin levels, increased DNA repair, and altered
doxorubicin-topoisomerase interaction. Investigations are
continuing in our laboratory to determine which mechanisms
of resistance of lung tumours are active.
The authors are indebted to Drs. I. Vogt-Moykopf and P. Drings
(Chest Hospital Rohrbach-Heidelberg) for providing tumour
material.
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